Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXOTCMKTS:GTHPNASDAQ:HYPRNASDAQ:ICCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.27-6.6%$1.53$0.17▼$1.99$4.13M0.514.05 million shs43,788 shsGTHPGuided Therapeutics$0.23$0.13$0.06▼$0.23$18.15M-0.113,089 shs5,897 shsHYPRHyperfine$0.70-0.1%$0.70$0.53▼$1.90$54.51M0.95897,724 shs214,238 shsICCMIceCure Medical$0.95+0.8%$1.07$0.48▼$1.66$52.33M0.33469,709 shs125,625 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-6.58%-15.30%-24.33%+992.92%+36.75%GTHPGuided Therapeutics0.00%+15.00%+84.00%+130.00%+53.33%HYPRHyperfine-0.16%-16.15%+11.78%-18.92%-15.76%ICCMIceCure Medical+0.76%-7.77%-7.32%-24.00%+20.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AGTHPGuided TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHYPRHyperfine2.2878 of 5 stars3.33.00.00.00.62.50.6ICCMIceCure Medical2.4956 of 5 stars3.85.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AGTHPGuided Therapeutics 0.00N/AN/AN/AHYPRHyperfine 2.67Moderate Buy$1.0651.60% UpsideICCMIceCure Medical 3.50Strong Buy$2.50163.16% UpsideCurrent Analyst Ratings BreakdownLatest GTHP, HYPR, CTCX, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.505/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.683/28/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.50 ➝ $2.503/24/2025HYPRHyperfineLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.503/20/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.50 ➝ $1.20(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,445.06N/AN/A$1.07 per share2.12GTHPGuided Therapeutics$10K1,814.93N/AN/A($0.12) per share-1.92HYPRHyperfine$12.89M4.22N/AN/A$0.67 per share1.04ICCMIceCure Medical$3.29M16.03N/AN/A$0.12 per share7.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AGTHPGuided Therapeutics-$2.42M-$0.05N/A∞N/AN/AN/A-197.32%8/12/2025 (Estimated)HYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/6/2025 (Estimated)ICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)Latest GTHP, HYPR, CTCX, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/15/2025Q1 2025GTHPGuided TherapeuticsN/A-$0.01N/A-$0.01N/AN/A5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million3/31/2025Q4 2024GTHPGuided TherapeuticsN/A-$0.02N/A-$0.02N/AN/A3/27/2025Q4 2024ICCMIceCure Medical-$0.07-$0.08-$0.01-$0.08$1.07 million$1.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AGTHPGuided TherapeuticsN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29GTHPGuided TherapeuticsN/A0.140.03HYPRHyperfineN/A6.075.48ICCMIceCure Medical0.021.891.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%GTHPGuided Therapeutics9.69%HYPRHyperfine15.03%ICCMIceCure Medical0.62%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%GTHPGuided Therapeutics66.83%HYPRHyperfine30.98%ICCMIceCure Medical2.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableGTHPGuided Therapeutics578.91 million26.18 millionNot OptionableHYPRHyperfine19077.83 million53.72 millionOptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionableGTHP, HYPR, CTCX, and ICCM HeadlinesRecent News About These CompaniesIceCure Medical (NASDAQ:ICCM) Trading Up 0.8% - Should You Buy?June 19 at 1:55 AM | americanbankingnews.comIceCure Medical (NASDAQ:ICCM) Trading Up 0.8% - Here's What HappenedJune 19 at 1:52 AM | marketbeat.comIceCure Medical: IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient OutcomesJune 10, 2025 | finanznachrichten.deIceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient OutcomesJune 9, 2025 | prnewswire.comHC Wainwright Reiterates "Buy" Rating for IceCure Medical (NASDAQ:ICCM)May 30, 2025 | marketbeat.comIcecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ...May 29, 2025 | finance.yahoo.comIceCure Medical (NASDAQ:ICCM) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPSMay 29, 2025 | marketbeat.comIceCure Medical Ltd (NASDAQ:ICCM) Q1 2025 Earnings Call TranscriptMay 29, 2025 | insidermonkey.comIceCure Medical Ltd (ICCM) Q1 2025 Earnings Call TranscriptMay 28, 2025 | seekingalpha.comIceCure (ICCM) Q1 2025 Earnings Call TranscriptMay 28, 2025 | msn.comIceCure Medical Reports First Quarter 2025 Financial ResultsMay 28, 2025 | prnewswire.comEarnings Preview For Icecure MedicalMay 27, 2025 | benzinga.comIceCure Medical (ICCM) Expected to Announce Earnings on TuesdayMay 22, 2025 | marketbeat.comIceCure Medical Secures $2 Million Bridge Loan from EpochMay 21, 2025 | tipranks.comIceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025May 21, 2025 | prnewswire.comIceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® CryoablationMay 6, 2025 | prnewswire.comIceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast CancerApril 30, 2025 | prnewswire.comIceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging SymposiumApril 28, 2025 | prnewswire.comIceCure ProSense Cryoablation Evaluated in Treatment for Breast CancerApril 23, 2025 | evtoday.comIceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer CryoablationApril 22, 2025 | prnewswire.comIceCure Medical Stock Dips Despite Positive ICESECRET Study ResultsMarch 28, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHP, HYPR, CTCX, and ICCM Company DescriptionsCarmell NASDAQ:CTCX$2.27 -0.16 (-6.58%) As of 06/17/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Guided Therapeutics OTCMKTS:GTHP$0.23 0.00 (0.00%) As of 06/18/2025 03:49 PM EasternGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Hyperfine NASDAQ:HYPR$0.70 0.00 (-0.11%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.11%) As of 06/18/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.IceCure Medical NASDAQ:ICCM$0.95 +0.01 (+0.76%) Closing price 06/18/2025 03:56 PM EasternExtended Trading$0.97 +0.02 (+1.68%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
